Legend Biotech posts $597M preliminary CARVYKTI sales

Legend Biotech Corporation reported preliminary net trade sales of approximately $597 million for CARVYKTI® for the quarter ended March 31, 2026.

Rhea-AI Filing Summary

Legend Biotech Corporation reported preliminary net trade sales of approximately $597 million for CARVYKTI® for the quarter ended March 31, 2026. This figure comes from collaboration partner Janssen under an existing collaboration and license agreement and has not been independently verified by Legend Biotech.

Management has not yet finalized the financial statements for this period, so the ultimate revenue and gross profit that Legend Biotech will record may differ from this sales figure. The company notes that its independent registered public accountants have not audited or reviewed this data and emphasizes customary forward-looking statement and risk factor cautions.

Insights

Biopharma equity analyst

Preliminary CARVYKTI® sales of $597M highlight product momentum but remain unaudited.

Legend Biotech disclosed that CARVYKTI® generated about $597 million in net trade sales for the quarter ended March 31, 2026, based on data from collaboration partner Janssen. This underlines CARVYKTI® as a central commercial driver within Legend’s portfolio.

The company stresses that this is a Janssen-reported figure, not yet independently verified, and that its auditors have not performed procedures on the data. Final revenue and gross profit recognized in Legend’s own statements may differ once management completes its accounting process.

Forward-looking statements around CARVYKTI® sales and profitability are subject to typical biopharma risks, including clinical outcomes, regulatory actions, intellectual property challenges, partner performance, competition, and pricing pressures, as referenced in the company’s Form 20-F risk factors.

Key Figures

CARVYKTI net trade sales: $597 million

1 metrics

CARVYKTI net trade sales $597 million Quarter ended March 31, 2026; preliminary figure from Janssen

Key Terms

net trade sales, Collaboration and License Agreement, forward-looking statements, independent registered public accountants, +1 more

5 terms

net trade sales financial

"CARVYKTI® generated approximately $597 million in net trade sales during the quarter"

Collaboration and License Agreement financial

"Pursuant to the Collaboration and License Agreement dated as of December 21, 2017"

A collaboration and license agreement is a legal contract where two or more parties agree to work together on developing or selling a product or technology while granting one another specific rights to use patents, know‑how, or other intellectual property. For investors, it matters because such deals can bring upfront payments, milestone or royalty income, and shared development costs and risks—like two neighbors pooling tools to renovate a house, which can speed progress and change future revenue potential.

forward-looking statements regulatory

"Statements in this report on Form 6-K about future expectations, plans and prospects ... constitute “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

independent registered public accountants regulatory

"Legend Biotech’s independent registered public accountants have not audited, reviewed or performed any procedures"

Independent registered public accountants are external auditing firms licensed to examine a public company’s financial records and issue an objective opinion on whether the financial statements are accurate and follow accounting rules. They matter to investors because their independent check is like a neutral referee confirming the score in a game — it reduces the risk of errors or misleading information and helps investors trust the financial reports used to make decisions.

Risk Factors regulatory

"as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report on Form 20-F"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What preliminary CARVYKTI sales did Legend Biotech (LEGN) report for Q1 2026?

Legend Biotech reported that CARVYKTI® generated approximately $597 million in net trade sales for the quarter ended March 31, 2026. This preliminary figure comes from its collaboration partner Janssen and will inform, but not determine, revenue and gross profit recorded in Legend’s financial statements.

How were Legend Biotech (LEGN) CARVYKTI sales for Q1 2026 determined?

The CARVYKTI® net trade sales figure of about $597 million was provided to Legend Biotech by Janssen under their collaboration and license agreement. Legend Biotech has not independently verified the accuracy of this data and will finalize its own revenue recognition after completing its financial statements.

Are Legend Biotech’s (LEGN) preliminary CARVYKTI sales for Q1 2026 audited?

No, the preliminary CARVYKTI® sales of approximately $597 million are unaudited. Legend Biotech states its independent registered public accountants have not audited, reviewed, or performed procedures on this information and have not expressed any opinion or assurance regarding the disclosed sales data.

Will Legend Biotech (LEGN) record $597 million of CARVYKTI revenue for Q1 2026?

Not necessarily. The $597 million represents CARVYKTI® net trade sales reported by Janssen, not Legend’s recognized revenue. Legend Biotech notes that actual revenue and gross profit in its consolidated statement of operations will be determined after management completes its financial statements for the period.

What risks could affect Legend Biotech’s (LEGN) future CARVYKTI results?

Legend Biotech cites risks such as uncertainties in developing new pharmaceutical products, unexpected clinical trial results, regulatory actions or delays, partner-related delays, intellectual property challenges, competition, and pricing pressures. These are further detailed in the Risk Factors section of its Form 20-F filed March 10, 2026.

How is this Legend Biotech (LEGN) Form 6-K used in other SEC registrations?

Legend Biotech states that this Form 6-K is incorporated by reference into its registration statements on Form F-3 (Nos. 333-278050, 333-272222, 333-257625) and Form S-8 (Nos. 333-239478, 333-283217), unless later filings or reports supersede the information included here.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/14/2026 - 07:30 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

Date of Report: April 14, 2026

Commission File Number: 001-39307

Legend Biotech Corporation

(Exact Name of Registrant as Specified in its Charter)

2101 Cottontail Lane

Somerset, New Jersey 08873

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  ☒            Form 40-F  ☐

Legend Biotech Announces Preliminary Sales for CARVYKTI^® for the Quarter Ended March 31, 2026

Pursuant to the Collaboration and License Agreement dated as of December 21, 2017, as amended, between Legend Biotech USA Inc., Legend Biotech Ireland Limited, Janssen Biotech, Inc. and Janssen Pharmaceutica NV (together, “Janssen”), on April 14, 2026, Legend Biotech Corporation (“Legend Biotech”) announced that CARVYKTI^® generated approximately $597 million in net trade sales during the quarter ended March 31, 2026. The net trade sales figure is based on information provided to Legend Biotech by Janssen, and Legend Biotech has not independently verified the accuracy of such sales figure.

The sales figure is based on information available to Legend Biotech as of the date of this Form 6-K, and the determination of the amount of any revenue or gross profit to be recorded in Legend Biotech’s consolidated statement of operations is subject to completion by management of Legend Biotech of its financial statements as of and for the period ended March 31, 2026. Legend Biotech’s independent registered public accountants have not audited, reviewed or performed any procedures with respect to this data and accordingly they have not expressed an opinion or provided any other form of assurance with respect thereto.

Cautionary Note Regarding Forward-Looking Statements

Statements in this report on Form 6-K about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to CARVYKTI^®, including Legend Biotech’s expectations for net trade sales and resulting gross profit of CARVYKTI^®. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Legend Biotech’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including as a result of additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays, including requests for additional safety and/or efficacy data or analysis of data, or government regulation generally; unexpected delays as a result of actions undertaken, or failures to act, by our third party partners; uncertainties arising from challenges to Legend Biotech’s patent or other proprietary intellectual property protection, including the uncertainties involved in the U.S. litigation process; competition in general; government, industry, and general public pricing and other political pressures; as well as the other factors discussed in the “Risk Factors” section of the Legend Biotech’s Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 10, 2026. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Form 6-K as anticipated, believed, estimated or expected. Any forward-looking statements contained in this Form 6-K speak only as of the date of this Form 6-K. Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

This report on Form 6-K is hereby incorporated herein by reference in the registration statements of Legend Biotech on Form F-3 (Nos. 333-278050, 333-272222 and 333-257625) and Form S-8 (No. 333-239478 and 333-283217), to the extent not superseded by documents or reports subsequently filed.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	LEGEND BIOTECH CORPORATION
Date: April 14, 2026	By:	/s/ Ying Huang
	Name:	Ying Huang, Ph.D.
	Title:	Chief Executive Officer